Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Sneha Gullapalli, Jordi Remon*, Lizza El Hendriks, Gilberto Lopes

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)6885-6896
Number of pages12
JournalOncotargets and Therapy
Volume13
DOIs
Publication statusPublished - 14 Jul 2020

Keywords

  • durvalumab
  • non-small cell lung cancer
  • PACIFIC
  • rechallenge
  • MYSTIC
  • PLATINUM-BASED CHEMOTHERAPY
  • STAGE-III NSCLC
  • CHEMORADIOTHERAPY REGIMEN
  • PHASE-III
  • PEMBROLIZUMAB
  • NIVOLUMAB
  • EFFICACY
  • OUTCOMES
  • 1ST-LINE
  • SAFETY

Cite this